TY - JOUR
T1 - The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells
AU - Thordardottir, Soley
AU - Hangalapura, Basav N.
AU - Hutten, Tim
AU - Cossu, Marta
AU - Spanholtz, Jan
AU - Schaap, Nicolaas
AU - Radstake, Timothy R D J
AU - Van Der Voort, Robbert
AU - Dolstra, Harry
PY - 2014/5/1
Y1 - 2014/5/1
N2 - The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to induce immunity in patients with cancer or infectious diseases. Despite promising expansion of antigen-specific T cells, the clinical responses following vaccination have been limited, indicating that further improvements of DC vaccine potency are necessary. Pre-clinical studies suggest that vaccination with combination of primary DC subsets, such as myeloid and plasmacytoid blood DCs (mDCs and pDCs, respectively), may result in stronger clinical responses. However, it is a challenge to obtain high enough numbers of primary DCs for immunotherapy, since their frequency in blood is very low. We therefore explored the possibility to generate them from hematopoietic progenitor cells (HPCs). Here, we show that by inhibiting the aryl hydrocarbon receptor with its antagonist StemRegenin 1 (SR1), clinical-scale numbers of functional BDCA2+BDCA4+ pDCs, BDCA1+ mDCs, and BDCA3+DNGR1+ mDCs can be efficiently generated from human CD34+ HPCs. The ex vivo-generated DCs were phenotypically and functionally comparable to peripheral blood DCs. They secreted high levels of pro-inflammatory cytokines such as interferon (IFN)-α, interleukin (IL)-12, and tumor necrosis factor (TNF)-α and upregulated co-stimulatory molecules and maturation markers following stimulation with Toll-like receptor (TLR) ligands. Further, they induced potent allogeneic T-cell responses and activated antigen-experienced T cells. These findings demonstrate that SR1 can be exploited to generate high numbers of functional pDCs and mDCs from CD34 + HPCs, providing an alternative option to Mo-DCs for immunotherapy of patients with cancer or infections.
AB - The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to induce immunity in patients with cancer or infectious diseases. Despite promising expansion of antigen-specific T cells, the clinical responses following vaccination have been limited, indicating that further improvements of DC vaccine potency are necessary. Pre-clinical studies suggest that vaccination with combination of primary DC subsets, such as myeloid and plasmacytoid blood DCs (mDCs and pDCs, respectively), may result in stronger clinical responses. However, it is a challenge to obtain high enough numbers of primary DCs for immunotherapy, since their frequency in blood is very low. We therefore explored the possibility to generate them from hematopoietic progenitor cells (HPCs). Here, we show that by inhibiting the aryl hydrocarbon receptor with its antagonist StemRegenin 1 (SR1), clinical-scale numbers of functional BDCA2+BDCA4+ pDCs, BDCA1+ mDCs, and BDCA3+DNGR1+ mDCs can be efficiently generated from human CD34+ HPCs. The ex vivo-generated DCs were phenotypically and functionally comparable to peripheral blood DCs. They secreted high levels of pro-inflammatory cytokines such as interferon (IFN)-α, interleukin (IL)-12, and tumor necrosis factor (TNF)-α and upregulated co-stimulatory molecules and maturation markers following stimulation with Toll-like receptor (TLR) ligands. Further, they induced potent allogeneic T-cell responses and activated antigen-experienced T cells. These findings demonstrate that SR1 can be exploited to generate high numbers of functional pDCs and mDCs from CD34 + HPCs, providing an alternative option to Mo-DCs for immunotherapy of patients with cancer or infections.
UR - http://www.scopus.com/inward/record.url?scp=84899100948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899100948&partnerID=8YFLogxK
U2 - 10.1089/scd.2013.0521
DO - 10.1089/scd.2013.0521
M3 - Article
C2 - 24325394
AN - SCOPUS:84899100948
VL - 23
SP - 955
EP - 967
JO - Stem Cells and Development
JF - Stem Cells and Development
SN - 1547-3287
IS - 9
ER -